Table 3. Exploratory modeling, stratified by event type.
| CNS NAE | PNS NAE | ||
|---|---|---|---|
| Variable | OR (95% CI) | Variable | OR (95% CI) |
| Tumor primary (reference Other) | Tumor primary (reference Other) | ||
| Lung | 0.49 (0.12–2.05) | Lung | 1.17 (0.45–3.03) |
| Melanoma | 3.95 (1.31–11.95) | Melanoma | 3.44 (1.22–9.71) |
| Renal Cell Carcinoma | 6.44 (1.92–21.58) | Renal Cell Carcinoma | 4.66 (1.45–15.02) |
| Comorbidities | Comorbidities | ||
| Neurological | 2.96 (1.05–8.36) | Neurological | 4.77 (0.59–38.28) |
| Obesity | 2.11 (0.90–4.95) | Irritable Bowel Disease | 0.26 (0.04–1.94) |
| Cardiovascular disease | 0.53 (0.20–1.39) | Obesity | 0.20 (0.05–0.86) |
| Psychiatric | 1.80 (0.87–3.71) | ||
| Peptic Ulcer Disease | 3.76 (1.10–12.88) | ||
Neurological comorbidities include cerebrovascular accident – transient ischemic attack – hemiplegia – dementia – and others.
Cardiovascular comorbidities include coronary vascular disease – prior myocardial infarction – peripheral arterial disease.
Peptic ulcer disease comorbidity includes any history of treatment.
Psychiatric comorbidity includes requiring psychiatric consult – medication – or other treatment.
‘Other tumor primary’ includes: breast, cervical, cutaneous squamous, endometrial, esophageal, gastric, hepatocellular, Hodgkin lymphoma, Merkel cell, urothelial.
CNS: Central nervous system; irAE: Immune-related adverse event; NAE: Neurological adverse event; PNS: Peripheral nervous system.